Twist Bioscience rated Hold as $9.5bn valuation outpaces fundamentals despite AI-driven stock surge.

Twist Bioscience's stock surged 200% recently, fueled by AI news and strong revenue growth, but its $9.5 billion valuation seems disconnected from current fundamentals. The company raised its 2026 revenue guidance to about $456–$457 million with a goal of adjusted EBITDA breakeven, yet it continues to face losses and high selling expenses. The stock's future depends on potential AI-driven healthcare market growth, but near-term volatility and speculative trading dominate. Investors should be cautious as profitability remains elusive despite optimistic forecasts.